We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Richard Burr (R-N.C.) will soon introduce revised legislation to strengthen the federal government’s efforts to fight bioterrorism and pandemic flu. But the bill already faces a new critic: HHS.
The Agency for Healthcare Research and Quality (AHRQ) is rejecting the biotechnology industry’s call for limits in how AHRQ applies its comparative effectiveness data, arguing the suggestions are outside the scope of the agency’s mandate.
The Agency for Healthcare Research and Quality (AHRQ) is rejecting the biotechnology industry’s call for limits in how AHRQ applies its comparative effectiveness data, arguing the suggestions are outside the scope of the agency’s mandate.
Prioritizing applications for off-patent drugs is one way to eradicate the backlog of generic drug applications at the Office of Generic Drugs (OGD), according to a top FDA official.
The FDA is not doing enough to ensure that its employees’ outside activities comply with federal conflict-of-interest requirements, according to an HHS Office of Inspector General (OIG) report — a conclusion the FDA rejects.
Noninvasive tests for breast cancer may not detect cancers in some women and are not accurate enough to routinely replace biopsies for women who receive abnormal findings from mammograms, says a recent study by the Agency for Healthcare Research and Quality, a division of the HHS.
The overall costs of the Medicare Rx drug benefit are dropping due to stronger than expected competition in the prescription drug market and lower drug costs, according to HHS officials.
Increased generic drug use and stronger-than-expected competition in the prescription drug market have driven down the overall costs of the Medicare Rx drug benefit, according to HHS officials.
The Agency for Healthcare Research and Quality’s (AHRQ) initiative to recommend preferred treatment options for a variety of health conditions could limit access to some medical therapies, especially if AHRQ’s efforts focus unduly on costs, say pharmaceutical and device manufacturers.
Low-income seniors are on the verge of losing industry assistance to pay for their medications when they sign up for the Medicare Rx benefit because of a standoff between the Centers for Medicare & Medicaid Services (CMS) and drug companies over whether the programs violate anti-kickback laws.